# A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of Desipramine

> **NCT01358968** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 20 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** LY2603618
- **DRUG:** Desipramine
- **DRUG:** Pemetrexed
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT01358968
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2012-04
- **Final completion:** 2012-12
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2018-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01358968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01358968, "A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of Desipramine". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01358968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*